A Multi-Center Open-Labeled Study of Recombinant Erythropoietin-Β in the Treatment of Anemic Patients with Multiple Myeloma, Low-Grade Non-Hodgkin’s Lymphoma, or Chronic Lymphocytic Leukemia in Chinese Population
Shen Yang,Ma Jun,Zhu Hong-Li,Wang Jian-Min,Wang Chun,Qiu Lu-Gui,Zhao Yong-Qiang,Zhu Jun,Hou Jian,Shen Zhi-Xiang
DOI: https://doi.org/10.1007/s12185-008-0130-3
2008-01-01
International Journal of Hematology
Abstract:The purpose of this study is to investigate the efficacy and safety of recombinant erythropoietin-β in the treatment of anemic patients with multiple myeloma (MM), low-grade non-Hodgkin’s lymphoma (NHL), and chronic lymphocytic leukemia (CLL). From December 2005 to November 2006, the patients with MM, low-grade NHL, and CLL were enrolled in this study, male or female, aged ≥18 years, transfusion-dependant, and receiving anti-neoplasia chemotherapy. Recombinant human erythropoietin-β was used in this study with the dose initiated at 150 IU/kg, thrice a week, subcutaneously. The total treatment duration was 12 weeks. The primary endpoint of the study is response rate (RR), which is defined as hemoglobin increasing ≥2 g/dL comparing to baseline level, or returning to normal range, without any transfusion within 6 weeks of evaluation. Fifty out of 82 (64.6%) patients enrolled in this study responded to the treatment and 29 patients had no response. Hypertension (12.2%) is the most common adverse effect; however, all the adverse events were mild, categorized in NCI grade I or II. We conclude that recombinant erythropoietin-β was effective in the treatment of anemia of the patients with MM, NHL, and CLL, as well as it is well-tolerated.